ENTXW (Entera Bio) PB Ratio: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTXW Entera Bio Ltd ENTXW
27 GF Score
Price $0.00
! 4 Warning Signs
View Full Analysis

What is Entera Bio PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-09), Entera Bio's share price is $0.0012. Entera Bio's Book Value per Share for the quarter that ended in Jun. 2026 was $0.00. Hence, Entera Bio's PB Ratio of today is .

Warning Sign:

Entera Bio Ltd stock PB Ratio (=20.54) is close to 10-year high of 20.54.

The historical rank and industry rank for Entera Bio's PB Ratio or its related term are showing as below:

ENTXW' s PB Ratio Range Over the Past 10 Years
Min: 1.01   Med: 4.58   Max: 20.54
Current: 20.54

During the past 11 years, Entera Bio's highest PB Ratio was 20.54. The lowest was 1.01. And the median was 4.58.

ENTXW's PB Ratio is ranked worse than
93.74% of 1215 companies
in the Biotechnology industry
Industry Median: 2.99 vs ENTXW: 20.54

During the past 12 months, Entera Bio's average Book Value Per Share Growth Rate was -61.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -11.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -14.40% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Entera Bio was -3.90% per year. The lowest was -35.70% per year. And the median was -11.40% per year.

Back to Basics: PB Ratio


Entera Bio  (NAS:ENTXW) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Entera Bio PB Ratio Related Terms


Entera Bio PB Ratio Historical Data

* Premium members only.

The historical data trend for Entera Bio's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio PB Ratio Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entera Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ENTXW vs CABA, KYTX, SCTX: PB Ratio Comparison

For the Biotechnology subindustry, Entera Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's PB Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's PB Ratio falls into.


ENTXW
27GF Score
Entera Bio Ltd ENTXW
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Entera Bio's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=0.0012/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Entera Bio Business Description

Other Exchanges ENTX:USA5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
27GF Score

Get the complete analysis for ENTXW

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price